Case report

Paraneoplastic cerebellar degeneration heralding recurrence of fallopian tube adenocarcinoma: A case report and literature review

Abigail Cain, Lindsey Buckingham, Allison Staley, Leslie H. Clark

A R T I C L E  I N F O

Keywords:
Paraneoplastic syndrome
Cerebellar degeneration
Fallopian tube cancer
Anti-Yo antibodies

1. Introduction

Paraneoplastic neurologic syndromes (PNS) are a spectrum of rare immune-mediated disorders that occur in approximately 1 in 10,000 patients with cancer (Rosenfeld and Dalmau, 2018). Given the association between PNS and cancer, if PNS is suspected, screening for a malignant source should be initiated.

PCD has been associated with fewer than 1% of cancers—these include gynecologic malignancies, breast cancer, small-cell carcinoma and Hodgkin Lymphoma (Le May and Dent, 2018; Bataller and Dalmau, 2003). Paraneoplastic cerebellar degeneration is a diagnosis of exclusion. The absence of brain metastases must be confirmed when symptoms of PCD arise (Le May and Dent, 2018). A literature review of all known cases of PCD in patients with ovarian and fallopian tube carcinoma was performed and is summarized in Table 1. Symptoms of PCD include sub-acute but progressive gait disturbances, truncal and appendicular ataxia, dysarthria, dysphagia, vertigo, nystagmus, and dysplopia (Bataller and Dalmau, 2003). An estimated 20% of patients will develop mild memory and cognitive deficits with rare cases causing cerebellar cognitive affective syndrome (CAS) which can cause decrease in executive function, spatial cognition, visual-spatial memory and disinhibited or inappropriate behavior (Le May and Dent, 2018). These symptoms progress over the course of months, plateauing at 6 months, and often stabilize with treatment but generally are not reversible, often leaving the patient severely disabled.

PCD is mediated by a cross-reaction of antibodies with tumor antigens in cerebellar tissue causing loss of Purkinje cells, variable thinning of the granular layer, and inflammatory infiltrates and gliosis in the deep cerebellar nuclei (Bataller and Dalmau, 2003). There are over 30 different autoantibodies associated with PCD (Le May and Dent, 2018); the most common of which include anti-Hu, anti Ri/Nova, and anti-Yo. Anti-Yo antibodies, sometimes referred to as Purkinje cell cytoplasmic antibody (PCA1) are most associated with gynecological cancers (Negishi, 2014); however, their incidence is very low. In one study of 557 patients with ovarian cancer, only 2.3% of patients were positive for the antibody, and only 12% of those had clinical evidence of PCD (Le May and Dent, 2018).

In this report, we describe the case of a 64-year-old woman who developed PCD and was subsequently found to have recurrence of her cancer.

2. Case description

Patient MK presented with Stage IV B high-grade serous carcinoma of the fallopian tube and underwent primary R0 debulking and adjuvant chemotherapy and noted to have no evidence of disease on computed tomography (CT) scan in March 2019. Following primary therapy, the patient was enrolled on a phase III clinical trial of oral PARP inhibitor rucaparib versus placebo and IV nivolumab versus placebo and began treatment in March 2019.

The patient presented in early November 2019 reporting increasing dizziness and poor balance. Neurologic examination was without abnormalities. Patient was noted to have immunotherapy induced hypothyroidism with TSH 50.9 and free T4 0.29 and was started on levothyroxine.

Twice in the next two weeks the patient presented to the emergency department due to worsening dizziness, lightheadedness, and nausea. On the second presentation, in mid-November, she was admitted for...
expedited evaluation. Her presentation was complicated by severe anxiety. Endocrinology was consulted during this admission and noted that her free T4 had normalized. Symptoms were felt to be not completely explained by hypothyroidism. As such, the pituitary and adrenal function were assessed and found to be normal. The Neurology team completely explained by hypothyroidism. As such, the pituitary and adrenal function were assessed and found to be normal. The Neurology team then consulted, and proceeded with nerve conduction studies, lumbar puncture, and MRI brain that showed no abnormalities. In this case given no focal defects and no abnormality in the results, the patient was discharged with plan for follow up with her oncologist in 1 week and instruction on canalith repositioning maneuvers.

At home, the patient experienced worsening gait disturbance resulting in several falls. She developed new dysarthria and had worsening emotional lability with increasing tearfulness. Paraneoplastic panel returned in December, she was noted to have + Anti-Yo Antibodies and diagnosed with Paraneoplastic cerebellar degeneration in December 2019. CT abdomen pelvis was obtained and showed mildly enlarged pelvic lymph nodes and her CA 125 had doubled from her baseline concerning for platinum-sensitive recurrence of her fallopian tube cancer.

The patient was admitted to the hospital for expedited treatment of PCD, both neurology and psychiatry teams were consulted. She received a 5-day course of pulse dose IV methylprednisolone and single agent carboplatin chemotherapy and underwent 2 cycles. Unfortunately, the patient experienced minimal improvement in her neurologic status and ultimately elected to discontinue cytotoxic therapy to pursue hospice care.

---

### Table 1

| Reference | Age | Time Interval | Initial Symptoms | Diagnosis of Malignancy | Timeline | Treatment | Outcome |
|-----------|-----|---------------|------------------|-------------------------|----------|-----------|---------|
| O’Brien et al. (1995) | 62 | 2 months | Gait unsteadiness, Limb clumsiness, Transient diplopia | Metastatic Adenocarcinoma of the ovary | Recurrence | Plasmapheresis Cyclophosphamide | Stable, until death |
| Matsuoka (1996) | 70 | 3 months | Dizziness, Vertigo, Nausea | Stage 3c Adenocarcinoma of the fallopian tube | Primary diagnosis | Glioplaxin Doxorubicin Cyclophosphamide | Stable |
| Matsuoka (1996) | 57 | 13 months | Diplopia, Dysarthria | Stage 1c Adenocarcinoma of the fallopian tube | Primary diagnosis | Glioplaxin Doxorubicin Cyclophosphamide | Stable |
| Levits et al. (2001) | 81 | 2 months | Diplopia, Tinnitus | Serous adenocarcinoma | Primary diagnosis | Methylprednisolone Paclitaxel | Stable |
| Tanaka (2005) | 63 | 1 month | Dizziness, Vertigo | Stage IIIc Serous adenocarcinoma fallopian tube | Primary diagnosis | Paclitaxel Carboplatin | Stable |
| Selby (2011) | 61 | 3 months | Diplopia, Ataxia, Vertigo | Grade 3, serous carcinoma of the fimbria, with underlying invasion but no vascular invasion | Primary diagnosis | IVIG Rituximab infusion Carboplatin | Stable |
| Russo et al. (2013) | 64 | – | Dystaxia, Truncal and limb ataxia, Dysgraphia, Nystagmus | Stage IIIc Serous papillary adenocarcinoma of the fallopian tube | Late onset | IVIG Corticosteroids Paclitaxel Carboplatin | Progressive decline |
| López et al. (2013) | 64 | 2 months | Gait disturbance, Dysarthria | Metastatic Endometrioid adenocarcinoma of the fallopian tube | Primary diagnosis | IVIG Carboplatin | Stable |
| Negishi (2014) | 62 | 1 month | Dysphasia, Vertigo | Stage IIIc Clear cell carcinoma of the ovary | Primary diagnosis | Methylprednisolone Paclitaxel | Stable |
| Haggerty et al. (2015) | 59 | – | Dizziness, Vertigo | Stage IIA Adenocarcinoma of the fallopian tube | Primary diagnosis | IVIG Carboplatin | Stable |
| Elomrani (2014) | 80 | less than 1 month | Dizziness, Vertigo | Metastatic Gynecological cancer not otherwise specified | Primary diagnosis | Paclitaxel Carboplatin | Progressive decline |
| Saeed and Gupta (2014) | 68 | 2 months | Ataxia, Dysarthria, Recurrent falls | Stage 3c Serous adenocarcinoma of the ovary | Primary diagnosis | Carboplatin | Improvement, Moderate |
| Kumari (2014) | 65 | 3 months | Gait disturbance | Stage IIIC Malignancy of the ovary | Primary diagnosis | Paclitaxel Carboplatin | Stable |
| Li (2015) | 37 | 2 month | Dizziness, Vertigo | Serous papillary cystadenocarcinoma of the ovary | Primary diagnosis | Paclitaxel Carboplatin | Improvement, Moderate |
| Chien et al. (2015) | 44 | 3 months | Dizziness, Vertigo, Nausea/Vomiting | Stage IIIC Serous carcinoma of the ovary | Primary diagnosis | Paclitaxel | Not reported |
| Cui et al. (2017) | 65 | – | Vertigo, Gait disturbance | Stage III Serous carcinoma of the ovary | Late onset, no definitive evidence of recurrence at 19 months | IVIG Methylprednisolone | Improvement, Significant |
| Renjen et al. (2018) | 65 | 2 months | Gait disturbance | Stage III A1 Serous adenocarcinoma of the ovary | Primary diagnosis | IVIG Carboplatin Paclitaxel | Improvement, Moderate |

---

- Not documented.
- Type of chemotherapy not documented.
3. Discussion

In the present report, we describe the case of a patient who developed PCD 10 months after completion of initial treatment for fallopian tube carcinoma. She presented initially with vague neurological symptoms that progressively worsened over the course of a two-month period. During this period her symptoms were attributed to hypothyroidism, BPPV and medication side effect. This highlights the importance of considering PCD as a potential cause for symptoms such as vertigo and loss of balance in a patient with cancer remission. The clinical picture in this scenario was particularly clouded by concern for immune toxicity due to study medications, which may have ultimately delayed the appropriate diagnosis in her case.

Early detection of PCD is paramount as in most cases of PCD associated with fallopian tube cancer, there was minimal response to therapy, however prior cases along their journey to diagnosis of PCD. As such, it is important for patients to recognize the most common symptoms in PCD, including ataxia in gait instability, and dysarthria. In general, symptoms worsen over time in gynecological cancers, initial symptoms are most commonly vertigo, loss of balance in a patient with cancer remission. The complaint of ataxia, dysarthria, or diplopia given that in a few cases treatment with intravenous immunoglobulin, plasmapheresis and chemotherapy were able to stop the progression of the neurological symptoms. It appears that the key is early detection and treatment to avoid rapid progression of neurologic dysfunction.

As opposed to the present case, PCD usually pre-dates a cancer diagnosis, or rarely, heralds the diagnosis of a recurrence. PCD has been described prior to the appearance of primary tumor in fallopian tube carcinomas, however, there have been no reports of PCD heralding a recurrence in fallopian tube carcinomas. On average, time between a patient's initial symptoms and the diagnosis of PCD and subsequent cancer diagnosis is 2.7 months with a range of 2 weeks–13 months (Negishi, 2014; O'Brien et al., 1995; Matuchita, 1998; Levine et al., 2001; Tanaka, 2005; Selby, 2011; Russo et al., 2013; López et al., 2013; Haggerty et al., 2015; Elomrani, 2014; Saeed and Gupta, 2014; Kumari, 2001; Tanaka, 2005; Selby, 2011; Russo et al., 2013; López et al., 2013; Le May, 2001). In gynecological cancers, initial symptoms are most commonly vertigo, gait instability, and dysarthria. In general, symptoms worsen over time and patients are often diagnosed with BPPV or other neurologic disorders along their journey to diagnosis of PCD. As such, it is important to recognize the most common symptoms in PCD, including ataxia in both trunk and limbs, dysarthria, nystagmus, diplopia, and dysphagia.

Our patient with PCD exhibited significant alterations in mood, personality change, and disinhibition which have rarely been reported in cases of PCD. Patients with degenerative cerebellar disease can have increased rates of psychiatric disorders specifically mood disorders and personality changes (Key and Root, 2013). These are related to both neuropsychiatric syndromes as well as the reaction to new onset of disabilities. Physiologically there are anatomic connections between the cerebellum and the prefrontal cortex, parahippocampal areas, posterior parietal, temporal and occipital lobes (Key and Root, 2013). There are few reports of psychiatric symptoms associated with PCD even though there is a growing body of evidence for the role of the cerebellum in cognition, mood and affect regulation (Key and Root, 2013).

This patient’s case highlights the importance of a wide differential including paraneoplastic syndromes in patients with gynecologic cancers in remission.

Author contributions

Abigail Cain: Assisted in drafting and editing case report, performed literature review, provided oncologic care to patient.

Linsey Buckingham: Reviewed case report, provided oncologic care to patient.

Allision Staley: Reviewed case report, provided oncologic care to patient.

Leslie H. Clark: Edited and assisted in drafting case report, provided oncologic care to patient.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Bataller, L., Dalmau, J., 2003. Paraneoplastic neurologic syndromes. Neurol. Clin. N. Am. 21 (3), 221–247. https://doi.org/10.1016/S0733-8619(02)00037-3.

Chien, H.J., et al., 2015. Paraneoplastic cerebellar degeneration in a patient with ovarian cancer. Taiwan. J. Obset. Gynecol. 54 (3), 313–315. https://doi.org/10.1016/j.jjog.2014.03.012.

Cui, D., et al., 2017. Anti-Yo positive and late-onset paraneoplastic cerebellar degeneration associated with ovarian carcinoma: A case report. Medicine (Baltimore) 96 (32). https://doi.org/10.1097/MD.0000000000017362.

Elomrani, F., et al., 2014. Ovarian cancer revealed by paraneoplastic cerebellar degeneration: a case report. Pan. Afr. Med. J. 2014 (18), 2. https://doi.org/10.11604/pan-2014.18.2.2808.

Haggerty, A.F., et al., 2015. Surgical diagnosis of stage I fallopian tube cancer in Anti-Yo antibody paraneoplastic cerebellar degeneration. J. Obset. Gynaecol. 35 (1), 100–101. https://doi.org/10.3109/01443615.2014.930095.

Key, R.G., Root, J., 2013. Anti-Yo mediated paraneoplastic cerebellar degeneration in the context of breast cancer: a case report and literature review. Psycho-Oncology 2013 (22), 2152–2155. https://doi.org/10.1002/pon.3270.

Kumari, V.A., et al., 2014. Paraneoplastic cerebellar degeneration. J. Obset. Gynaecol. Res. 40, 1463–1465. https://doi.org/10.1111/jog.12331.

Le May, M., Dent, S., 2018. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review. Curr. Oncol. 25 (6). https://doi.org/10.3747/co.25.4106.

Levine, R., et al., 2001. Paraneoplastic cerebellar degeneration heralding fallopian tube adenocarcinoma. Int. J. Gneural Cancer 11 (2), 169-171. https://doi.org/10.1046/j.1525-1438.2001.01102616.x.

Li, W.H., et al., 2015. A rare case of ovarian cancer presenting with paraneoplastic cerebellar degeneration and limbic encephalitis. Chin. Med. J. 2015 (128), 2685–2687. https://doi.org/10.4103/0366-6999.166028.

López, N.O., et al., 2013. Paraneoplastic cerebellar degeneration as initial presentation of papillary carcinoma of the fallopian tube: evaluation and usefulness of (18F-FDG PET-CT. Case report and literature review. Nucl. Med. Mol. Imaging 47 (1), 55–60. https://doi.org/10.1016/s1319-012-0180-6.

Matuchita, H., et al., 1998. Paraneoplastic cerebellar degeneration with anti-purkinje cell antibody associated with primary tubal cancer. Gynecol. Obset. Invest. 1998 (45), 140–143. https://doi.org/10.1159/000009942.

Negishi, Y., et al., 2014. Paraneoplastic cerebellar degeneration. J. Obset. Gynaecol. Res. 40, 614–617. https://doi.org/10.1007/s12221-014-2293-y.

O’Brien, T.J., et al., 1995. Anti-Yo positive paraneoplastic cerebellar degeneration: a report of three cases and review of the literature. J. Clin. Neurosci. 2 (4), 316–320. https://doi.org/10.1016/0967-5868(95)90052-7.

Renjen, P.N., et al., 2018. Paraneoplastic cerebellar degeneration associated with ovarian adenocarcinoma: a case report and review of literature. Ann. Indian Acad. Neurol. 21 (4), 311–314. https://doi.org/10.4103/ainn.AIAN.2014.17.

Rosenfeld, M., Dalmau, J., 2018. Paraneoplastic neurologic syndromes. Neurol. Clin. 36 (2018), 675–685. https://doi.org/10.1016/j.ncl.2018.04.015.

Russo, A.E., et al., 2013. Paraneoplastic cerebellar degeneration associated with ovarian cancer. Oncol. Lett. 5 (2), 681–683. https://doi.org/10.3892/ol.2012.1016.

Saeed, D.B., Gupta, L., 2014. Paraneoplastic cerebellar degeneration associated with serous adenocarcinoma of the ovary. BMJ Case Rep. 2014(4). https://doi.org/10.1136/bcr-2014-206377. bcr2014206377.

Selby, K., et al., 2011. Anti-Yo antibody associated with occult fallopian tube carcinoma. Int. J. Gynecol. Pathol. 2011 (30), 536–538. https://doi.org/10.1097/PGP.0b013e31823273c6.

Tanaka, Y., et al., 2005. Paraneoplastic cerebellar degeneration with fallopian tube adenocarcinoma. Gynecol. Obset. Oncol. 99 (2005), 500–503. https://doi.org/10.1016/j.jygyno.2005.06.064.